Benign schwannoma

Benign schwannoma, also known as neurilemmoma or neurinoma, is a benign nerve sheath tumor that arises from Schwann cells, which are the cells responsible for producing the myelin sheath that insulates peripheral nerves. These tumors are typically slow-growing, well-encapsulated, and can develop along any peripheral nerve, cranial nerve, or spinal nerve root. The most commonly affected sites include the head and neck region, the flexor surfaces of the upper and lower extremities, and the posterior mediastinum. When arising from cranial nerves, the vestibular nerve (cranial nerve VIII) is most frequently involved, giving rise to vestibular schwannoma (acoustic neuroma), though these are classified separately. Schwannomas occurring in peripheral soft tissues are classified under ICD-10 code D36.1. Key symptoms depend on the tumor's location and size. Many benign schwannomas are asymptomatic and discovered incidentally. When symptomatic, patients may experience a palpable, slowly enlarging mass, localized pain or tenderness, tingling or numbness in the distribution of the affected nerve, and occasionally neurological deficits such as weakness if the tumor compresses adjacent nerve fibers. Spinal schwannomas may cause radiculopathy or myelopathy. The vast majority of schwannomas are solitary and sporadic, though multiple schwannomas can occur in the context of genetic syndromes such as neurofibromatosis type 2 (NF2) or schwannomatosis (now termed SMARCB1- or LZTR1-related schwannomatosis). The primary treatment for symptomatic benign schwannomas is surgical excision, which is usually curative with low recurrence rates due to the tumor's encapsulated nature. Because these tumors typically displace rather than infiltrate nerve fibers, nerve-sparing surgery is often possible. For asymptomatic or incidentally discovered tumors, a watch-and-wait approach with periodic imaging may be appropriate. Malignant transformation of solitary benign schwannomas is exceedingly rare. Prognosis is generally excellent, with most patients experiencing complete resolution of symptoms following surgical removal.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Benign schwannoma